Biomarker discovery in clinical proteomics is being performed on relatively large patient cohorts by utilizing the high throughput of laser desorption/ionization mass spectrometry (MALDI-and SELDI-TOF-MS). Dealing directly with patient samples as opposed to working in cell or animal systems requires a host of considerations both before and after mass spectrometric analysis to obtain robust biomarker candidates. The challenges associated with the heterogeneity of typical samples are amplified by the ability to detect hundreds to thousands of proteins simultaneously. Adherence to protocols and consistency, however, can ensure optimal results. A study starts necessarily with a relevant clinical question and proceeds to a planning phase where sample availability, statistical test selection, logistics and bias reduction are key points. The physical analysis requires consistency and standardized protocols that are helped significantly through automation. Data analysis is broken into two stages, screening and final testing, which can detect either single candidates or a pattern of proteins. Biomarker identification can be performed at this point and will help significantly in the last stage, interpretation. Replication should be performed in an independent sample set in a separate study. The candidate biomarkers from an initial study give a wealth of information that can help to pinpoint patient subpopulations for a more exhaustive proteomic study using complementary platforms with limited capacity but extremely high information content. A clinical proteomics pilot project can also lead to better selection of model systems by providing a direct link with patient samples.
INTRODUCTION
Genetic research in the field of diabetes celebrated a milestone recently with the publication of several genome wide association (GWA) studies [1] [2] [3] [4] . In connection with the first article, Freimer and Sabatti wrote, 'To evaluate GWA studies, we must revise our notion that a discovery in human genetics consists of identifying ''the gene'' for a disease. This notion derives from investigations of rare diseases, which could, in a single study, be associated definitively with mutations in a single gene' [5] . The same holds true for proteomic and epigenetic studies of multi-factorial diseases, such as diabetes and cancer. On top of complicated disease mechanisms, the expression and interactions of proteins are multimodal and are controlled on the DNA, RNA and protein levels. Changes at any level can result in altered protein expression and coupled with their involvement in interaction networks, which often lead to post-translational modifications, the detectable level of any given protein at any point in time depends on a multitude of variables [6] . While such a dynamic picture of the proteome would seemingly make an investigation in proteomics an impossible task, protein biomarkers are well established in medicine and that means that biological responses, such as disease progression, must have common factors that cause significant alterations in expression.
The highly interactive nature of proteins, however, may mean that the levels that are most altered may not be directly involved in any given biological process. In this way candidate biomarkers that are seemingly unrelated to a process, but predictably change levels in response to a disease state can most certainly be used as surrogate markers. Just as important to remember going forward is that while finding a single specific biomarker for a disease process is not out of the question, it will indeed be a lofty goal to set at the start of any project.
Protein biomarker discovery is an evolving and rich field that abounds with different strategies but lacks a unified approach. A typical suggested route could start with the in-depth analysis of a handful of samples (model systems or pooled human serum) using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) followed by tailored LC-MS/MS-based assays and eventually the testing of candidate biomarkers on a larger scale using immunoassays [7] . The switch in technology platforms is currently difficult to avoid in this type of approach because of cost and throughput considerations. An alternative is to start with a significantly larger number of patient samples, so-called clinical proteomics. The applicability of clinical proteomics was proven in an ovarian cancer study from 2002 and even though the results have spawned a fair bit of debate, the study itself was pioneering and has helped to shape the field [8, 9] . In the intervening years, the search for ovarian cancer biomarkers to complement or even replace CA-125 has been documented in a number of groups and the commercialization of a test in one form or another may be a reality in the near future [10] . Clinical proteomics is growing rapidly as has been documented in several recent reviews, especially in the field of cancer, and attempts to define quality levels have now started even that long-term experience in the field is still ahead of us [11] [12] [13] .
Both matrix assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS, MALDI for short) and surface enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS, SELDI for short) are proteomics platforms capable of running a significant number of samples in a short time and can be used for biomarker discovery from clinical samples. While there has been some debate concerning the performance of the two platforms, especially SELDI, both are excellent biomarker discovery tools with differing strengths. In contrast to MALDI, which is sold by several companies in many different instrument designs, SELDI has a single instrument type with unique characteristics. The technique as it is available is simple and rapid and has a high sensitivity at larger masses (>10 kDa) but the advantages compromise other performance aspects such as peak resolution and mass precision. It was elegantly shown recently that proteomics platforms are complementary to an extremely high degree and strategies employing multiple techniques, such as MALDI and SELDI in clinical proteomics, for biomarker discovery projects have the potential to increase the number of biomarker candidates from the same sample set [14] . Mass spectrometric platforms, however, are only part of a successful biomarker discovery program as a host of challenges still remain and most of them are present before analysis commences or during data analysis and interpretation.
BIOMARKER DISCOVERY STRATEGIES
The real goal for a candidate biomarker is to make its way into the hands of clinicians as soon as possible, but the journey from bench to bedside is arduous. Despite significant advances the field of clinical proteomics is still maturing and lacks the first generally accepted protein biomarker that was discovered using mass spectrometric-based proteomic screening in a multi-factorial disease. Quite a bit of effort, however, is being invested in recognizing and overcoming some of the challenges associated with measuring biomolecules with a huge dynamic range (>1 Â 10 10 ) directly in large numbers of human samples instead of a handful of samples from model systems, which are considerably more homogenous and can be kept under strict control [15] . The issue of bias, both analytical and biological, has been set into focus and is addressed on many levels including recent results that suggest that some of the previous success stories may have been tainted by bias [16] [17] [18] . The subject is not new or unique to mass spectrometry (MS) but is amplified by the sensitive measurement of tens or hundreds of protein species simultaneously. While the field has a huge potential to detect a series of novel protein biomarkers, the same potential also exists for detecting biomarkers for sample differences that are not necessarily clinically relevant, such as gradients in storage temperatures, collection protocol changes or uneven numbers of freeze/thaw cycles. It is often easier to detect differences between collection sites, presumably due to slight differences in local procedures, than to detect changes directly related to the study goal (J. McGuire, unpublished data). To help in planning and discussions, projects can be broken down into five phases with distinct obstacles and considerations (see Figure 1) .
CLINICAL RELEVANCE
The starting point of a successful study is a relevant clinical question and appropriate samples. Many studies, especially in cancer and Alzheimer's disease (AD), have focused on diagnosing a disease state at as early stage as possible. Published ovarian cancer studies have focused on an earlier and more accurate diagnosis and have not excluded the possibility of incorporating an existing biomarker, CA-125, along with their candidates discovered by proteomics [10] . A recent report in the field of cancer was able to show that different patterns of detected peptides, which are presumably formed through exoproteolytic activity, were specific to three different cancer types and opens the door for testing peptides directly as surrogate markers for changes in proteolytic activities accompanying specific disease processes [19, 20] . The concept of proteomics being a detection method for response proteins that are surrogates of biological activity had also been presented in ovarian cancer [21] . Candidate biomarkers studies in AD have now been performed in stages as early as mild cognitive impairment, which does not necessarily develop to AD, and identifying which patients are most at risk for progression would be extremely beneficial to clinicians and caretakers [22, 23] .
The number of samples required for a study is dependent not only on the goal but also availability and success criteria, which should be set at the very beginning to avoid reformulating the goal to fit the acquired data. This is not to say that unexpected results should be discarded but rather that they should be treated as a new study that can give exciting results as long as all variables that should be accounted for are checked thoroughly. In the case of a relatively rare disease, it may be necessary to start a study with fewer samples and while this may weaken eventual statistical analyses, it may still add valuable information that could be checked at other institutions. Other diseases, such as type 1 diabetes, which have a clinical manifestation in a relatively dynamic population that may be difficult to strictly match due to disease debut at differing ages, may need to rely on relatively large sample numbers for new protein biomarkers. The situation may be even more complicated considering that existing biomarkers, such as human leukocyte antigen genotypes, islet autoantibodies and antibodies to beta-cell specific antigens, can only partially describe disease risk. In this case, it may be necessary to find candidate biomarkers for subpopulations. The same may also be true for complicated biological responses, such as success of drug treatment. In theory it should be possible to stratify patients into potential responders and non-responders; although, in practice interpretation of both proteomic and clinical data may be necessary as different groups of patients may respond positively for a variety of reasons.
STUDY PARAMETERS
As the success of a study is based on finding differences in comparison with control samples, it is essential that controls have equivalently high Figure 1 : Phases of a clinical proteomics project. The process is iterative and requires careful planning from the first phases, addressing a relevant clinical question and setting study parameters. The choice of an analysis platform is not limited to MS, which is currently the technology of choice due to its throughput and a high number of variables that can be analysed simultaneously. Data analysis can be performed using established statistical tools and protein identification is accomplished using protein chemistry. Interpretation of results is essential and may lead to a reanalysis or further to replication. quality levels. At a minimum their collection should be standardized and they should be matched as much as possible. The other study parameters can be set after establishing a goal and success criteria and details from this stage are now starting to appear in the proteomics literature although it will take time to fully evaluate and implement standard procedures [13] . The number of samples included in a pilot phase study is extremely important and is highly dependent on both the sample availability and the chosen analysis platform. As a general rule of thumb sample number should be large enough to reliably discover biomarker candidates using a particular statistical test, which should be selected prior to analysis to ensure that methods are chosen to test rather than to fit the starting hypothesis. The logistics with regard to future steps and eventual follow-up studies should ideally be set at this point to ensure a standardization of procedures, which should strive to be at as high a quality level as possible but should necessarily be consistent. Sample and data tracking should also be established before starting the study to ensure that everyone involved knows how to access material and results. Great care should be taken as well to accommodate the nature of data generated in the proceeding step, physical analysis.
PHYSICAL ANALYSIS
As has been covered amply in the proteomics literature, a small number of species dominate the total protein concentration in plasma and serum while the vast majority of proteins comprise only about 1% of the total concentration [24] . In the analysis of many biological matrices, mainly plasma and serum, an initial fractionation can increase the resolution of proteins in the sample by minimizing overlapping signals and increasing the number of detectable species (see summary in Table 1 ). One of the most frequently used techniques for separation are various gels, where proteins can be separated according to their molecular volume (sufficiently similar to the molecular weight), by their isoelectric point or combined as in two-dimensional gels (2D-gels), where the coupling of the separation parameters gives an increase in resolving power such that thousand of proteins and peptides can be separated in a single process [25] . Another classical fractionation technique is liquid chromatography (LC), which takes advantage of the proteins difference in hydrophobicity, ionic charge and molecular mass. LC is usually quicker and more reproducible than gel separation because of less manual handling and has the ability to allow preparation of proteins on a larger scale [26] . A limitation of both techniques is their relatively low throughput that has the potential to give rise to significant analytical bias.
The invention of resin-based separation products has made it possible to deplete samples in a parallel manner in microtiter plate format using liquid handling robots, thereby improving the reproducibility. Historically, serum albumin was partially depleted with Cibracon Blue dye-based resins and that approach is still popular as it is cost effective and commercial resins can now remove over 90% of albumin and can be implemented in a parallel fashion. Newer approaches for removal of high concentration serum and plasma proteins using affinity columns based on antibodies exist but are expensive or have a low throughput or both. Common protein chromatographic surfaces, including anion exchange and reversed phase, are becoming increasingly popular where all methods are based on relatively small starting volumes of serum and can be run in microtiter plates on standard robotic platforms [27] . Emerging technologies, such as ligand-based bead libraries, are capable of depleting the small number of proteins that dominate the proteome while concentrating the others. The relatively low cost allows parallel processing of hundreds of samples so that access to the lower abundance proteins in the material is possible while securing that samples are processed in a similar manner [28] [29] [30] [31] . After sample fractionation, which is still necessary with existing platforms, analysis moves to the instrument side, which is summarized in Table 2 and is routinely reviewed to keep pace with new developments [32, 33] . Two basic proteomic characterization strategies exist in a variety of platforms: bottom-up and topdown. In the bottom-up, or shotgun, approach all proteins are digested with enzymes and the generated peptides are separated and analysed [34] . In this approach, candidate biomarkers are identified as relatively small fragments of whole proteins generated by cleavage with an enzyme and not as true biomarker candidates complete with biologically relevant modifications or isoform differences. Furthermore, the processing of data generated from samples requires substantial time and makes the method unsuitable for large sample cohorts [35] . In the top-down strategy nascent peptides and proteins are detected directly. This approach has the capacity to detect whole peptides and proteins as they occur and better represents the phenotypic variation amongst individuals. Both approaches are based on MS because of its sensitivity and rapidity [36] . The MS technique revolutionized the area of protein chemistry in the 1990s with the invention of the two soft ionization methods, electrospray ionization (ESI) and MALDI, where proteins and peptides are ionized without any fragmentation of the analytes [37, 38] . The techniques were quickly assimilated alongside classical methods of protein chemistry, such as nuclear magnetic resonance, X-ray crystallography and circular dichroism. MALDI is an extremely popular technology for peptide and protein analysis due to its low cost per sample and the high throughput rate. SELDI is an alternative, and much debated, MS technique for biomarker discovery. It has an advantage in directly incorporating a separation step prior to analysis. Sample complexity is reduced by fractionation based on selective interactions of proteins with different selective surfaces [39] . The sample is further mixed with a matrix, as in MALDI, and analysed similarly. This simple and user friendly technology has become increasingly popular when analysing proteomes, but its potential has also been intensely debated [40] . A reported drawback of the method is the lack of comparability of generated datasets due to the difference in the chemical matrices on the various chip surfaces although this was partially dispelled [41] . Another critique of the method is the reproducibility over multiple experiments, where it has proven difficult to generalize the results from one experiment to another [9] . Other researchers, however, have successfully completed large, multicentre studies and initial lack of replication may simply be important contributions to a learning curve in a new field [21, 42] . Analysis of unfractionated material by SELDI allows comparison of a large number of samples, but the resolution of the technique is limited. This can be overcome by Limited instrument resolution and mass accuracy.
Data analysis
processing the material before submitting it to SELDI along with utilizing a complementary and appropriate MS such as MALDI [43] . When searching for candidate biomarkers, it is crucial to aim for a high level of consistency and reproducibility when considering the choice of technique. Samples for analysis are ideally processed in a parallel fashion to help ensure that variability in the results is due to biologically differences and not to sample processing artefacts.
DATA ANALYSIS AND IDENTIFICATION
An advantage with clinical proteomics is that it opens the door to analyse data using a host of proven statistical methods and adds considerable power to calculations. This stands in contrast to sample groups that must be pooled prior to analysis to accommodate a particular technology if it lacks sufficient reproducibility and throughput. For a two group comparison, let us say treated and placebo, sample pooling reduces not just biological variation but information content in the form of subtle changes that are not present in all patients [44] . For multifactorial diseases, such as cancer, AD and diabetes, the likelihood of finding a single specific biomarker does not look promising and running individual samples will provide a richer picture of candidate biomarkers that can be combined with other existing data in a prediction model. Pooling may also remove potential mechanistic information in the form of subtle protein alterations that are not present in all patients but correlate to specific phenotypes. Many strategies for analysing clinical proteomics data have been reported and most of them rely on the eventual detection of a collection of proteins that can distinguish different biological groups from one another (see Table 3 ). Individual peaks, however, can be treated as single variables (univariate approach) as is often done in an initial screening phase. The first step is a selection of the peaks with the best potential for fulfilling a study's success criteria. A student's t-test (unpaired or paired) or their non-parametric counterparts (Mann-Whitney U-test or Wilcoxon signed-rank test) can help sort potentially important peak clusters from those with no apparent relevance. Peak clusters should be checked for quality to ensure that only real signals are being carried forward and that they are labelled correctly. Patient cohorts can be relatively large but not so extensive at this point that peaks cannot be checked manually. If any peaks are relabelled then they should be retested. Peaks that pass the initial screen can be tested using more stringent significance criteria. The strongest candidates should be among the most significant peaks and in the case of a two group comparison a receiver operator characteristic (ROC) area under the curve (AUC) can be calculated. ROC AUC data includes information on a peak's potential to detect true positives (sensitivity) and true negatives (specificity). It is not uncommon that peaks are selected that have a relatively high sensitivity but a lower specificity and this can reflect an overemphasis on selection criteria for a disease group versus the control group, which may have had less stringent inclusion criteria.
Peaks can be combined in a multivariate approach as a filtering step, although this is not widely implemented, and afterwards using a classification algorithm [45] . Multivariate approaches can be split into two basic types, unsupervised and supervised. In unsupervised approaches, such as principal components analysis (PCA), group information is not part of model building. PCA is commonly used as a visualization tool and can alternatively function as a measure of how specific parameters (e.g. date, collection site, plate number) affect output variables (covariance analysis can also be used). Supervised techniques, such as decision tree algorithms The number of incorrect predictions increases with the complexity of the decision tree [52] . Support vector machine Superior at discriminating data in high dimensional parameter space [52, 53] .
Poor classification of blinded data when using high numbers of variables and dimensions because of overfitting.
(e.g. CART), neural networks or support vector machine algorithms, account for group placement when building a model. One of the strengths of supervised methods is that models are built that focus on the desired outcome with the potential drawback of overfitting. The risk of overfitting data can be minimized by keeping model complexity to a minimum. The eventual identification of candidate biomarkers, while not strictly necessary to build a statistical model, is extremely satisfying in helping to interpret data. In the adaption of MALDI instruments to protein profiling, an emphasis is placed on the low molecular weight proteome (peptidome) where candidates are relatively simple to identify using sequencing by MALDI-MS/MS. Larger peptides and proteins, however, are not yet directly identifiable and need to be partially purified and identified using microscale protein purification and in-gel digestion [46] . With the lack of a public database for either MALDI or SELDI, the top-down approach still requires off-line preparation of larger amounts of patient material for a positive identification. Fortunately, more and more proteins are being reported and masses can be checked at each step using the original platform in a fashion analogous to following a purification using an activity assay. Identifications can be corroborated using antibodybased detection (e.g. western blot or ELISA) or antibody pull-down with subsequent detection by MS.
INTERPRETATION
Interpretation of findings should be taken with an open mind as the sensitivity of most proteomics platforms will invariably lead to the discovery of proteins that are not known to be intimately involved in a disease process. Altered protein expression associated with a treatment or change in disease state, albeit indirectly, can still be used as a surrogate biomarker for a desired end point. Proteins are involved in arrays of networks and most likely exert their effects through relatively small changes of more than one member. Presumably complicated response patterns will mean that a portion of candidate biomarkers will be extremely difficult to capture in a replication study because they are sensitive to changes in patient cohorts and sample collection. Other candidate biomarkers will be more consistent across changes in different variables, but may still be sensitive to the same parameters that affect a particular disease state. For example, the rising incidence of type 2 diabetes in differing parts of Northern Europe, where populations are relatively homogeneous, can be explained by falling mortality rates, which are influenced by environmental variables and treatment methods [47] . Candidate biomarkers will likely be just as susceptible to slight changes and it will be extremely important to keep data over the course of several related studies. It may be the proteins that change subtly but consistently become more important in the long run than those that change most significantly in a pilot study.
REPLICATION
The current cost and workflows do not prohibit but are certainly not conducive to running large cohorts (1000 þ samples) and the switch to an orthogonal platform, such as traditional immunoassays or multiplexed systems, is inevitable. Immunoassays have been tested extensively in many settings and are a reliable analysis technique as long as suitable antibodies are available. As this is not always the case, several alternatives are emerging that include specific capture or selection of proteins and peptides based on tandem-MS methods or even the SELDI platform itself, which allows the specific capture of proteins based on their interactions with array surfaces in differing buffers [48] . While none of the methods are necessarily ready to run large numbers of samples, they will in the near future provide alternatives when antibodies are not available.
A single biomarker discovery study produces only candidates that can be considered to be true biomarkers when they have been replicated in independent samples. If this process starts with pooled samples then at one point or another the hurdle of biological variation, which is significant in human samples versus animal and cell models, needs to be overcome. If one starts with hundreds of samples that are analysed and processed in parallel then biological variation becomes an integral part of biomarker discovery. Along with natural variation, however, follows the need for consistency to allow for a higher success rate in replication studies. Failure of a candidate to be corroborated should not necessarily discard it from further evaluation as it may still be valuable in the context of its original discovery.
PERSPECTIVES
As the feasibility of starting a proteomics study on a relatively large sample cohort has been documented, especially in the field of cancer, the focus can now turn toward utilizing all of the options that such studies afford (see Figure 2 ). Platforms are highly complementary and choosing more than one will only add valuable information from precious samples [14] . Starting a proteomics study directly on patient samples adds benefits not available to long, linear studies and brings candidate biomarkers one step closer to replication, validation and clinical implementation. Looking at large patient populations without a prior list of candidates or hypothesized biomarkers will make it possible to find proteins that can help stratify patients. In the future this will open up drug candidate screening options by being able to address more specialized groups and could be extremely relevant going forward, especially if future drugs will be more focused or tailored than present ones.
Patient samples may also be selected on the basis of initial profiles from pilot studies for further proteomic analysis. The inherent information present in a clinical proteomics study can potentially give a boost to the power of emerging technologies that are designed to explore larger and larger portions of the proteome but cannot currently handle clinically relevant numbers of samples. The pooling of samples simply based on existing diagnostic criteria may not be the most efficient way of choosing patient samples for exhaustive proteomic analysis. Clinical data plus further information from an initial proteomics study can help to stratify patients. As an example, samples for the same disease diagnosed using accepted criteria in two different hospitals are generally easy to separate in a proteomic analysis. The simple solution is to only collect samples from one hospital. A potentially better approach is to choose patients from different sites with similar proteomes within their respective groups. In this way systematic and biological bias can be minimized.
The translation of results from model systems to humans is the basis for translational medicine and while the workflow goes traditionally in that direction in some fields, proteomics can go both ways. Translation the other way, from humans to model systems, could provide an alternative approach to ensure relevancy in humans. As a hypothetical example, let us say that protein X is a highly significant candidate biomarker in a rat model system while protein Y is less significant. Protein X would be a natural candidate to pursue further in human samples while protein Y would be overlooked even though it is a true candidate biomarker in human samples. If one starts with the human samples then protein Y could be translated back to the rat model system while protein X would not be considered. The establishment of relevancy in humans before looking in models can help researchers better mimic and tune systems to the human condition they should reflect and would benefit both pharmaceutical and basic researchers alike [49] .
A relatively untapped resource at this point is the combination of existing clinical data with candidate biomarker data. Reports have a tendency to focus on protein patterns discovered on a particular platform without incorporating background data on established biomarkers. Every patient sample has a wealth of existing data, including measurement of known risk factors that can be incorporated in a systems biology approach to better describe the state of an individual patient and how it relates to a desired outcome (e.g. disease prediction).
In order for a clinical proteomics approach to be widely successful, the methods need to be generally accessible-the current technologies MALDI, SELDI and multiplexed immunoassays have this potential. It should be possible for everyone on the spectrum from bench to bedside to perform these studies so that the domain of candidate biomarker discovery is not firmly planted in basic research labs. It's encouraging to see that SELDI has managed to accomplish this and leads the way for other technologies to follow. The advances in analysis of specific proteins without the necessity of affinity capture is exciting and have the potential to advance to the point that metabolomics is at today [50] . Advances in smaller scale devices, especially those with a ligand library based on an array instead of beads, combined with mass spectrometric analysis may eventually push the initial screen from hundreds to thousands of proteins in thousands of samples [51] . A crucial point will of course be affordability, which took many years in genomics but has now arrived in that field and will eventually be a reality in proteomics.
Higher throughput will necessitate constant improvements in all aspects of studies to ensure improved reproducibility. A sustainable and high level of reproducibility is essential to produce high quality data, which will ensure better bioinformatics, which is an area that is still blossoming in proteomics. With complicated disease states it is unlikely that only one highly specific biomarker exists and it will be important to discover the combinations of proteins that best correlate to the changes studied. High quality data from more and more patient samples should make it possible to find truly specific protein combinations even if most of the proteins themselves only change slightly.
